Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
01/06/2026 08:00 AM • Mdxhealth announced a collaboration with the University of Oxford to initiate Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial, the world's largest randomized clinical trial for localized prostate cancer treatment. This study aims to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, potentially impacting clinical practice guidelines and payer coverage.
MDXH - The company is advancing its GPS test through validation in the world's largest randomized prostate cancer trial, which could establish clinical credibility, influence treatment guidelines, and expand payer coverage. This represents significant progress in precision diagnostics and market positioning.
Investing.com • David Wagner